CUSIP: 56854Q101
Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
31,231,281
-
Share change
-
-2,575,325
-
Total reported value
-
$48,093,608
-
Put/Call ratio
-
24%
-
Price per share
-
$1.54
-
Number of holders
-
61
-
Value change
-
-$18,733,149
-
Number of buys
-
23
-
Number of sells
-
42
Quarterly Holders Quick Answers
What is CUSIP 56854Q101?
CUSIP 56854Q101 identifies MRNS - MARINUS PHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2019
-
Previous quarter:
Q2 2019
Recent filing periods for CUSIP 56854Q101:
Institutional Holders of MARINUS PHARMACEUTICALS INC - COM (MRNS) as of Q3 2019
As of 30 Sep 2019,
MARINUS PHARMACEUTICALS INC - COM (MRNS) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,231,281 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Granite Point Capital Management, L.P., BlackRock Inc., Lion Point Capital, LP, VHCP Management III, LLC, FRANKLIN RESOURCES INC, VANGUARD GROUP INC, VHCP Management II, LLC, Alyeska Investment Group, L.P., and 683 Capital Management, LLC.
This page lists
61
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.